eShowcase: Liquent InSight v. 3.5
Dual-purpose package allows submission in both paper and electronic formats
Dual-purpose package allows submission in both paper and electronic formats
Thomson Scientific (Philadelphia, PA, and London, UK) recently released the latest version of its regulatory compliance tool, InSight Publisher version 3.5. The latest iteration enables pharmaceutical companies to create, manage, and publish regulatory submissions in both paper and electronic form using a single software application, potentially saving critical time in the drug development process.
Around the world, regulatory authorities increasingly prefer the electronic format, yet they still require a paper version. With Liquent InSight version 3.5, life science professionals can produce both from a single assembly, using the same thin-client application integrated with the rest of the InSight software suite. Since it is built on the same platform as InSight Manager, which offers registration management and submission tracking capabilities, the entire platform is highly adaptable to different organizational processes and designs.
Thomson Scientific, (215) 386-0100, www.liquent.com
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
